摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-羟基-3-甲基苯硼酸 | 762263-66-1

中文名称
4-羟基-3-甲基苯硼酸
中文别名
3-甲基-4-羟基苯硼酸
英文名称
(4-hydroxy-3-methylphenyl)boronic acid
英文别名
——
4-羟基-3-甲基苯硼酸化学式
CAS
762263-66-1
化学式
C7H9BO3
mdl
——
分子量
151.958
InChiKey
GZHWHLOMMPXHPW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    358.0±52.0 °C(Predicted)
  • 密度:
    1.26±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.62
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    60.7
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:266fcccf4a6fc727af95b6ccbe510f4f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Hydroxy-3-methylbenzeneboronic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Hydroxy-3-methylbenzeneboronic acid
CAS number: 762263-66-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9BO3
Molecular weight: 152.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Novel Carbazole Inhibits Phospho-STAT3 through Induction of Protein–Tyrosine Phosphatase PTPN6
    摘要:
    The aberrant activation of STAT3 occurs in many human cancers and promotes tumor progression. Phosphorylation of a tyrosine at amino acid Y705 is essential for the function of STAT3. Synthesized carbazole derived with fluorophore compound 12 was discovered to target STAT3 phosphorylation. Compound 12 was found to inhibit STAT3-mediated transcription as well as to reduce IL-6 induced STAT3 phosphorylation in cancer cell lines expressing both elevated and low levels of phospho-STAT3 (Y705). Compound 12 potently induced apoptosis in a broad number of TNBC cancer cell lines in vitro and was effective at inhibiting the in vivo growth of human TNBC xenograft tumors (SUM149) without any observed toxicity. Compound 12 also effectively inhibited the growth of human lung tumor xenografts (A549) harboring aberrantly active STAT3. In vitro and in vivo studies showed that the inhibitory effects of 12 on phospho-STAT3 were through up-regulation of the protein-tyrosine phosphatase PTPN6. Our present studies strongly support the continued preclinical evaluation of compound 12 as a potential chemotherapeutic agent for TNBC and cancers with constitutive STAT3 signaling.
    DOI:
    10.1021/jm4018042
  • 作为产物:
    描述:
    2-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)苯酚sodium periodate 、 ammonium acetate 、 作用下, 以 丙酮 为溶剂, 反应 19.0h, 以36%的产率得到4-羟基-3-甲基苯硼酸
    参考文献:
    名称:
    FARNESOID X RECEPTOR AGONISTS
    摘要:
    本发明提供了新型的取代异噁唑化合物、药物组合物、治疗用途和制备方法。
    公开号:
    US20080096921A1
点击查看最新优质反应信息

文献信息

  • [EN] FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS À TITRE DE MODULATEURS DE S1P
    申请人:ABBVIE INC
    公开号:WO2017036978A1
    公开(公告)日:2017-03-09
    The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    这项发明涉及杂环化合物作为S1P调节剂,包括这种化合物的药物组合物,以及在治疗、缓解或预防由S1P受体介导的疾病或紊乱中的用途。
  • Pd- and Ni-Based Systems for the Catalytic Borylation of Aryl (Pseudo)halides with B<sub>2</sub>(OH)<sub>4</sub>
    作者:Charissa Munteanu、Taylor E. Spiller、Jun Qiu、Albert J. DelMonte、Steven R. Wisniewski、Eric M. Simmons、Doug E. Frantz
    DOI:10.1021/acs.joc.0c00929
    日期:2020.8.21
    complementary Ni-based catalyst system that employs simple unligated Ni(II) salts as an inexpensive alternative to the Pd-based systems for the borylation of aryl (pseudo)halides. Extrapolation of all three systems to a one-pot tandem borylation/Suzuki–Miyaura cross-coupling is also demonstrated on advanced intermediates and drug substances.
    尽管在金属催化的芳基(假)卤化物的硼化反应方面取得了最新进展,但仍需要开发出可靠的方法来获得可用于进一步官能化的早期和晚期有机硼中间体。尤其是,在广泛的亲电子伙伴中,在温和的反应条件下运行的通用催化系统的开发仍然难以实现。本文中,我们报道了使用四羟基二硼(B 2(OH)4)进行芳基(假)卤化物直接硼化的三种催化体系(两种基于Pd的体系和一种基于Ni的体系)的开发和应用)。对于基于Pd的催化剂体系,我们已经确定了一般的反应条件,该条件允许通过简单的沉淀来螯合卤离子,从而导致催化剂负载量低至0.01 mol%(100 ppm),反应温度低至室温。我们还描述了一种互补的基于Ni的催化剂体系,该体系采用简单的未连接的Ni(II)盐作为对基于Pd的芳基(假)卤化物进行硼化的体系的廉价替代品。在先进的中间体和原料药上,还证明了将所有三个系统外推至一锅串联硼化/ Suzuki-Miyaura交叉偶联。
  • Synthesis, binding affinity and structure–activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists
    作者:Anna Junker、Artur K. Kokornaczyk、Annelien J. M. Zweemer、Bastian Frehland、Dirk Schepmann、Junichiro Yamaguchi、Kenichiro Itami、Andreas Faust、Sven Hermann、Stefan Wagner、Michael Schäfers、Michael Koch、Christina Weiss、Laura H. Heitman、Klaus Kopka、Bernhard Wünsch
    DOI:10.1039/c4ob02397h
    日期:——
    of such complex, multifactorial disorders. Herein we report on the design, synthesis and biological evaluation of benzo[7]annulene- and [7]annulenothiophene-based selective and dual CCR2 and CCR5 receptor antagonists. Intermediates were designed in such a way that diversification could be introduced at the end of the synthesis. Starting from the lead compound TAK-779 (1), the quaternary ammonium moiety
    CCR2和CCR5受体在几种炎性,心血管和自身免疫性疾病的发生和发展中起关键作用。因此,两种受体的双重靶向吸引人作为治疗此类复杂,多因素疾病的有前途的策略。在这里,我们报告基于苯并[7]环戊烯和[7]环噻吩基选择性和双重CCR2和CCR5受体拮抗剂的设计,合成和生物学评估。中间体的设计方式是,可以在合成结束时引入多样化。从铅化合物TAK-779(1),季铵部分被不同的不带电部分交换,4-甲基苯基部分被广泛修饰,苯并[7]环戊烯核心被[7]环戊噻吩系统生物等位取代。萘基衍生物9h代表最有前景的双重拮抗剂(K i(CCR2)= 25 nM,IC 50(CCR5)= 17 nM),而6-异丙氧基-3-吡啶基和4-甲氧羰基苯基衍生物9k和9r显示出更多的抗药性。与CCR5受体相比,CCR2的选择性为20倍(K i = 19 nM)。
  • Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy
    作者:Junjie Luo、Zhiye Hu、Yuan Xiao、Tongxin Yang、Chune Dong、Jian Huang、Hai-Bing Zhou
    DOI:10.1039/c7md00163k
    日期:——

    Selenophenes with basic side chains showed excellent antagonist activity for ERs and increased antiproliferative activity than that of 4OHT in MCF-7 cells.

    含有碱性侧链的硒吲哚显示出对雌激素受体的优异拮抗活性,并且在MCF-7细胞中表现出比4OHT更强的抗增殖活性。
  • 一种八氟环戊烯基苯并环丁烯官能化单体及其制备与应用
    申请人:复旦大学
    公开号:CN112538004A
    公开(公告)日:2021-03-23
    本发明涉及一种八氟环戊烯基苯并环丁烯官能化单体及其制备与应用,所述的单体,具有如下所示结构:其中,R取代基为三氟甲基、氢原子、甲基、烯丙基或丙烯基。所述的单体制备方法为将八氟环戊烯和含有苯并环丁烯的化合物在溶剂和催化剂作用下反应得到。所述的单体可应用于制备耐高温、低介电的聚合物材料。与现有技术相比,本发明具有单体可后固化,后固化反应后可得到耐高温、低介电的聚合物材料,单体制备过程副反应少等优点。
查看更多